Pfizer might soon have a new version of its vaccine on the market that targets the omicron variant of COVID-19, which the company expects will be ready in March.
In an interview with CNBC’s Squawk Box on Monday, Pfizer CEO Albert Bourla said the company has already started manufacturing doses of the vaccine.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.